蛋白酶3(PR3)多克隆抗體

Polyclonal Antibody to Proteinase 3 (PR3)

MBN; PRTN3; ACPA; AGP7; C-ANCA; MBT; P29; PRK; Myeloblastin; Serine Proteinase,Neutrophil,Wegener Granulomatosis Autoantigen

  • 蛋白酶3(PR3)多克隆抗體產品包裝(模擬)
  • 蛋白酶3(PR3)多克隆抗體產品包裝(模擬)
  • 蛋白酶3(PR3)多克隆抗體DAB staining on IHC-P; Samples: Mouse Cerebrum Tissue; Primary Ab: 20μg/ml Rabbit Anti-Mouse PR3 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
  • 蛋白酶3(PR3)多克隆抗體DAB staining on IHC-P;
    Samples: Mouse Spleen Tissue;
    Primary Ab: 20μg/ml Rabbit Anti-Mouse PR3 Antibody
    Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • PAB434Mu01.jpgFigure. Western Blot; Sample: Recombinant PR3, Mouse.
  • 蛋白酶3(PR3)多克隆抗體Figure. Western Blot; Sample. Lane1: Mouse Lung Tissue; Lane2: Mouse Spleen Tissue.
  • Certificate通過ISO 9001、ISO 13485質量體系認證

特異性

該抗體是針對PR3的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別PR3。

用法

Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunofluorescence:5-20μg/mL;
Optimal working dilutions must be determined by end user.

儲存

經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產生。保質期內,在適當?shù)臈l件下存儲,損失率低于5%。

贈品

相關產品

編號適用物種:Mus musculus (Mouse,小鼠)應用(僅供研究使用,不用于臨床診斷!)
RPB434Mu01蛋白酶3(PR3)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAB434Mu01蛋白酶3(PR3)多克隆抗體WB; IHC; ICC; IP.
PAB434Mu02蛋白酶3(PR3)多克隆抗體WB; IHC; ICC; IP.
LAB434Mu71蛋白酶3(PR3)多克隆抗體(生物素標記)WB; IHC; ICC.
SEB434Mu蛋白酶3(PR3)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMB434Mu蛋白酶3(PR3)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻

雜志參考文獻
BioMed Research International VolumeAre Proteinase 3 and Cathepsin C Enzymes Related to Pathogenesis of Periodontitis?[Pubmed:24949444]
electronic thesis and dissertation repositoryRegulation of Leukocyte-Derived Matrix Metalloproteinases and Azurophilic Enzymes in Human Diabetic Ketoacidosis[Etd: 2869]
United States Patent ApplicationDIAGNOSIS AND THERAPY OF CHRONIC INFLAMMATION-INDUCED DISORDERS[y2016:0011207.html]